

Claims

What is claimed is:

1. A cyclic peptide comprising the sequence His-Ala-Val, wherein said cyclic peptide modulates cadherin-mediated cell adhesion.

2. A cyclic peptide according to claim 1, having the formula:



wherein X_1 , and X_2 are optional, and if present, are independently selected from the group consisting of amino acid residues and combinations thereof in which the residues are linked by peptide bonds, and wherein X_1 and X_2 independently range in size from 0 to 10 residues, such that the sum of residues contained within X_1 and X_2 ranges from 1 to 12;

wherein Y_1 and Y_2 are independently selected from the group consisting of amino acid residues, and wherein a covalent bond is formed between residues Y_1 and Y_2 ; and

wherein Z_1 and Z_2 are optional, and if present, are independently selected from the group consisting of amino acid residues and combinations thereof in which the residues are linked by peptide bonds.

3. A cyclic peptide according to claim 2, wherein Z_1 is not present and Y_1 comprises an N-acetyl group.

4. A cyclic peptide according to claim 2, wherein Z_2 is not present and Y_2 comprises a C-terminal amide group.

5. A cyclic peptide according to claim 2, wherein Y₁ and Y₂ are covalently linked via a disulfide bond.

6. A cyclic peptide according to claim 5, wherein Y₁ and Y₂ are each independently selected from the group consisting of penicillamine, β,β-tetramethylene cysteine, β,β-pentamethylene cysteine, β-mercaptopropionic acid, β,β-pentamethylene-β-mercaptopropionic acid, 2-mercaptopbenzene, 2-mercptoaniline, 2-mercaptoproline and derivatives thereof.

7. A cyclic peptide according to claim 5, wherein Y₁ and Y₂ are cysteine residues or derivatives thereof.

8. A cyclic peptide according to claim 7, wherein said cyclic peptide comprises the sequence Cys-His-Ala-Val-Cys (SEQ ID NO:8).

9. A cyclic peptide according to claim 8, further comprising an N-acetyl group.

10. A cyclic peptide according to claim 8, further comprising a C-terminal amide group.

11. A cyclic peptide according to claim 7, wherein said cyclic peptide comprises a sequence selected from the group consisting of Cys-Ala-His-Ala-Val-Asp-Ile-Cys (SEQ ID NO:10), Cys-Ser-His-Ala-Val-Cys (SEQ ID NO:12), Cys-His-Ala-Val-Ser-Cys (SEQ ID NO:14), Cys-Ala-His-Ala-Val-Asp-Cys (SEQ ID NO:16) and Cys-Ser-His-Ala-Val-Ser-Ser-Cys (SEQ ID NO:18).

12. A cyclic peptide according to claim 2, wherein Y₁ and Y₂ are covalently linked via an amide bond.

13. A cyclic peptide according to claim 12, wherein said amide bond is formed is formed between terminal functional groups.

14. A cyclic peptide according to claim 12, wherein said amide bond is formed between residue side-chains.

15. A cyclic peptide according to claim 12, wherein said amide bond is formed between one terminal functional group and one residue side chain.

16. A cyclic peptide according to claim 12, wherein:

(a) Y_1 is selected from the group consisting of lysine, ornithine, and derivatives thereof and Y_2 is selected from the group consisting of aspartate, glutamate and derivatives thereof; or

(b) Y_2 is selected from the group consisting of lysine, ornithine and derivatives thereof and Y_1 is selected from the group consisting of aspartate, glutamate and derivatives thereof.

17. A cyclic peptide according to claim 12, wherein said cyclic peptide comprises the sequence Lys-His-Ala-Val-Asp (SEQ ID NO:20) or Ala-His-Ala-Val-Asp-Ile (SEQ ID NO:44).

18. A cyclic peptide according to claim 2, wherein Y_1 and Y_2 are covalently linked via a thioether bond.

19. A cyclic peptide according to claim 2, wherein Y_1 and Y_2 are each tryptophan or a derivative thereof, such that said covalent bond generates a $\delta_1\delta_1$ -ditryptophan, or a derivative thereof.

20. A cyclic peptide according to any one of claims 1-19 linked to a targeting agent.

21. A cyclic peptide according to any one of claims 1-19 linked to a drug.
22. A cyclic peptide according to any one of claims 1-19 linked to a solid support.
23. A cyclic peptide according to claim 22, wherein said solid support is a polymeric matrix.
24. A cyclic peptide according to claim 23, wherein said solid support is selected from the group consisting of plastic dishes, plastic tubes, sutures, membranes, ultra thin films, bioreactors and microparticles.
25. A cyclic peptide according to any one of claims 1-19 linked to a molecule comprising a binding site for an adhesion molecule, wherein said adhesion molecule is not a cadherin.
26. A cyclic peptide according to any one of claims 1-19 linked to a detectable marker.
27. A pharmaceutical composition comprising a cyclic peptide according to any one of claims 1-19 in combination with a pharmaceutically acceptable carrier.
28. A composition according to claim 27, further comprising a drug.
29. A composition according to claim 28, wherein said drug is linked to said cyclic peptide.
30. A composition according to claim 27, wherein said cyclic peptide is present within a sustained-release formulation.

31. A method for modulating cell adhesion, comprising contacting a cadherin-expressing cell with a cyclic peptide according to any one of claims 1-19.

32. A method according to claim 31, wherein said cadherin is selected from the group consisting of E-cadherin and N-cadherin.

33. A method according to claim 31, wherein said cadherin is selected from the group consisting of P-cadherin, R-cadherin and other cadherins comprising the cell adhesion recognition sequence HAV.

34. A method according to claim 31, wherein said cell is selected from the group consisting of epithelial cells, endothelial cells, neural cells, tumor cells and lymphocytes.

35. A method according to claim 31, wherein said cyclic peptide inhibits cell adhesion.

36. A method for reducing unwanted cellular adhesions in a mammal, comprising administering to a mammal a cyclic peptide according to any one of claims 1-19.

37. A method for enhancing the delivery of a drug through the skin of a mammal, comprising contacting epithelial cells of a mammal with a cyclic peptide according to any one of claims 1-19 and a drug under conditions and for a time sufficient to allow passage of said drug across said epithelial cells.

38. A method according to claim 37, wherein said cyclic peptide passes into the blood stream of said mammal.

39. A method for enhancing the delivery of a drug to a tumor in a mammal, comprising administering to a mammal a composition according to claim 28.

40. A method according to claim 39, wherein said composition is administered to said tumor.

41. A method according to claim 39, wherein the tumor is selected from the group consisting of bladder tumors, ovarian tumors and melanomas.

42. A method according to claim 39, wherein said composition is administered by injection.

43. A method according to claim 39, wherein said composition is administered topically.

44. A method according to claim 39, wherein said composition is administered systemically.

45. A method for treating cancer in a mammal, comprising administering to a mammal afflicted with cancer a composition according to claim 27.

46. A method according to claim 45, wherein said cancer is selected from the group consisting of carcinomas, leukemia and melanomas.

47. A method for inhibiting metastasis of tumor cells in a mammal, comprising administering to a mammal a composition according to claim 26.

48. A method for inhibiting angiogenesis in a mammal, comprising administering to a mammal a composition according to claim 27.

49. A method for enhancing drug delivery to the brain of a mammal, comprising administering to a mammal a composition according to claim 28.

50. A method according to claim 49, wherein said composition is administered by injection.

51. A method according to claim 31, wherein said cyclic peptide enhances cell adhesion.

52. A method for enhancing wound healing in a mammal, comprising contacting a wound in a mammal with a cyclic peptide according to claim 23.

53. A method according to claim 52, wherein said composition comprises a cyclic peptide according to claim 3.

54. A method for enhancing adhesion of foreign tissue implanted within a mammal, comprising contacting a site of implantation of foreign tissue in a mammal with a cyclic peptide according to claim 23.

55. A method according to claim 54, wherein said foreign tissue is a skin graft or organ implant.

56. A method for inducing apoptosis in a cadherin-expressing cell, comprising contacting a cadherin-expressing cell with a cyclic peptide according to any one of claims 1-19.

57. A method for enhancing and/or directing neurite outgrowth, comprising contacting a neuron with a cyclic peptide according to any one of claims 1-19.

58. A method for treating spinal cord injuries in a mammal, comprising administering to a mammal a composition according to claim 27.

59. A method for treating spinal cord injuries in a mammal, comprising administering to a mammal a cyclic peptide according to claim 23.

60. A method for treating a demyelinating neurological disease in a mammal, comprising administering to a mammal a composition according to claim 28.

61. A method according to claim 60, wherein said disease is multiple sclerosis.

62. A method for modulating the immune system of a mammal, comprising administering to a mammal a composition according to claim 27.

63. A method for preventing pregnancy in a mammal, comprising administering to a mammal a composition according to claim 30.

64. A method according to claim 63, wherein the step of administering is intravaginal or intrauterine.

65. A method for increasing vasopermeability in a mammal, comprising administering to a mammal a composition according to claim 27.

66. A method for identifying a cyclic peptide capable of modulating cadherin-mediated cell adhesion, comprising:

(a) culturing neurons on a monolayer of cells that express N-cadherin in the presence and absence of a candidate cyclic peptide, under conditions and for a time sufficient to allow neurite outgrowth;

(b) determining a mean neurite length for said neurons; and

(c) comparing the mean neurite length for neurons cultured in the presence of candidate cyclic peptide to the neurite length for neurons cultured in the absence of candidate cyclic peptide, and therefrom identifying a cyclic peptide capable of modulating cell adhesion.

67. A method for identifying a cyclic peptide capable of modulating cadherin-mediated cell adhesion, comprising:

(a) culturing cells that express a cadherin in the presence and absence of a candidate cyclic peptide, under conditions and for a time sufficient to allow cell adhesion; and

(b) visually evaluating the extent of cell adhesion among said cells, and therefrom identifying a cyclic peptide capable of modulating cell adhesion.

68. A method according to claim 67, wherein said cells are selected from the group consisting of endothelial, epithelial and cancer cells.

69. A method for identifying a cyclic peptide capable of modulating cadherin-mediated cell adhesion, comprising:

(a) culturing NRK cells in the presence and absence of a candidate cyclic peptide, under conditions and for a time sufficient to allow cell adhesion;

(b) comparing the level of cell surface E-cadherin for cells cultured in the presence of candidate cyclic peptide to the level for cells cultured in the absence of candidate cyclic peptide, and therefrom identifying a cyclic peptide capable of modulating cell adhesion.

70. A method for identifying a cyclic peptide capable of modulating cadherin-mediated cell adhesion, comprising:

(a) contacting an epithelial surface of skin with a test marker in the presence and absence of candidate cyclic peptide; and

(b) comparing the amount of test marker that passes through said skin in the presence of candidate cyclic peptide to the amount that passes through skin in the absence of candidate cyclic peptide, and therefrom identifying a cyclic peptide capable of modulating cell adhesion.

71. A method according to claim 70, wherein said skin is human skin.

72. A method for identifying a cyclic peptide capable of modulating cadherin-mediated cell adhesion, comprising:

- (a) contacting a blood vessel with a candidate cyclic peptide; and
- (b) comparing the extent of angiogenesis of said blood vessel to a predetermined extent of angiogenesis observed for a blood vessel in the absence of candidate cyclic peptide, and therefrom identifying a cyclic peptide capable of modulating cell adhesion.

73. A kit for administering a drug via the skin of a mammal, comprising

- (a) a skin patch; and
- (b) a cyclic peptide according to any one of claims 1-19.

74. A kit according to claim 73, wherein said skin patch is impregnated with said cyclic peptide.

75. A kit according to claim 74, further comprising a drug.

76. A method for modulating cell adhesion, comprising contacting a cadherin-expressing cell with an antibody that binds to a cyclic peptide according to any one of claims 1-19.

77. A method for targeting a drug to a cadherin-expressing cell in a mammal, comprising administering to a mammal an antibody that binds to a cyclic peptide according to any one of claims 1-19, wherein said antibody is linked to a drug.

78. A method for detecting the presence of cadherin-expressing cells in a sample, comprising:

- (a) contacting a sample with an antibody that binds to a cyclic peptide according to any one of claims 1-19 under conditions and for a time sufficient to allow formation of an antibody-cadherin complex; and

52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
4410
4411
4412
4413
4414
4415
4416
4417
4418
4419
4420
4421
4422
4423
4424
4425
4426
4427
4428
4429
4430
4431
4432
4433
4434
4435
4436
4437
4438
4439
4440
4441
4442
4443
4444
4445
4446
4447
4448
4449
44410
44411
44412
44413
44414
44415
44416
44417
44418
44419
44420
44421
44422
44423
44424
44425
44426
44427
44428
44429
44430
44431
44432
44433
44434
44435
44436
44437
44438
44439
44440
44441
44442
44443
44444
44445
44446
44447
44448
44449
444410
444411
444412
444413
444414
444415
444416
444417
444418
444419
444420
444421
444422
444423
444424
444425
444426
444427
444428
444429
444430
444431
444432
444433
444434
444435
444436
444437
444438
444439
444440
444441
444442
444443
444444
444445
444446
444447
444448
444449
4444410
4444411
4444412
4444413
4444414
4444415
4444416
4444417
4444418
4444419
4444420
4444421
4444422
4444423
4444424
4444425
4444426
4444427
4444428
4444429
4444430
4444431
4444432
4444433
4444434
4444435
4444436
4444437
4444438
4444439
4444440
4444441
4444442
4444443
4444444
4444445
4444446
4444447
4444448
4444449
44444410
44444411
44444412
44444413
44444414
44444415
44444416
44444417
44444418
44444419
44444420
44444421
44444422
44444423
44444424
44444425
44444426
44444427
44444428
44444429
44444430
44444431
44444432
44444433
44444434
44444435
44444436
44444437
44444438
44444439
44444440
44444441
44444442
44444443
44444444
44444445
44444446
44444447
44444448
44444449
444444410
444444411
444444412
444444413
444444414
444444415
444444416
444444417
444444418
444444419
444444420
444444421
444444422
444444423
444444424
444444425
444444426
444444427
444444428
444444429
444444430
444444431
444444432
444444433
444444434
444444435
444444436
444444437
444444438
444444439
444444440
444444441
444444442
444444443
444444444
444444445
444444446
444444447
444444448
444444449
4444444410
4444444411
4444444412
4444444413
4444444414
4444444415
4444444416
4444444417
4444444418
4444444419
4444444420
4444444421
4444444422
4444444423
4444444424
4444444425
4444444426
4444444427
4444444428
4444444429
4444444430
4444444431
4444444432
4444444433
4444444434
4444444435
4444444436
4444444437
4444444438
4444444439
4444444440
4444444441
4444444442
4444444443
4444444444
4444444445
4444444446
4444444447
4444444448
4444444449
44444444410
44444444411
44444444412
44444444413
44444444414
44444444415
44444444416
44444444417
44444444418
44444444419
44444444420
44444444421
44444444422
44444444423
44444444424
44444444425
44444444426
44444444427
44444444428
44444444429
44444444430
44444444431
44444444432
44444444433
44444444434
44444444435
44444444436
44444444437
44444444438
44444444439
44444444440
44444444441
44444444442
44444444443
44444444444
44444444445
44444444446
44444444447
44444444448
44444444449
444444444410
444444444411
444444444412
444444444413
444444444414
444444444415
444444444416
444444444417
444444444418
444444444419
444444444420
444444444421
444444444422
444444444423
444444444424
444444444425
444444444426
444444444427
444444444428
444444444429
444444444430
444444444431
444444444432
444444444433
444444444434
444444444435
444444444436
444444444437
444444444438
444444444439
444444444440
444444444441
444444444442
444444444443
444444444444
444444444445
444444444446
444444444447
444444444448
444444444449
4444444444410
4444444444411
4444444444412
4444444444413
4444444444414
4444444444415
4444444444416
4444444444417
4444444444418
4444444444419
4444444444420
4444444444421
4444444444422
4444444444423
4444444444424
4444444444425
4444444444426
4444444444427
4444444444428
4444444444429
4444444444430
4444444444431
4444444444432
4444444444433
4444444444434
4444444444435
4444444444436
4444444444437
4444444444438
4444444444439
4444444444440
4444444444441
4444444444442
4444444444443
4444444444444
4444444444445
4444444444446
4444444444447
4444444444448
4444444444449
44444444444410
44444444444411
44444444444412
44444444444413
44444444444414
44444444444415
44444444444416
44444444444417
44444444444418
44444444444419
44444444444420
44444444444421
44444444444422
44444444444423
44444444444424
44444444444425
44444444444426
44444444444427
44444444444428
44444444444429
44444444444430
44444444444431
44444444444432
44444444444433
44444444444434
44444444444435
44444444444436
44444444444437
44444444444438
44444444444439
44444444444440
44444444444441
44444444444442
44444444444443
44444444444444
44444444444445
44444444444446
44444444444447
44444444444448
44444444444449
444444444444410
444444444444411
444444444444412
444444444444413
444444444444414
444444444444415
444444444444416
444444444444417
444444444444418
444444444444419
444444444444420
444444444444421
444444444444422
444444444444423
444444444444424
444444444444425
444444444444426
444444444444427
444444444444428
444444444444429
444444444444430
444444444444431
444444444444432
444444444444433
444444444444434
444444444444435
444444444444436
444444444444437
444444444444438
444444444444439
444444444444440
444444444444441
444444444444442
444444444444443
444444444444444
444444444444445
444444444444446
444444444444447
444444444444448
444444444444449
4444444444444410
4444444444444411
4444444444444412
4444444444444413
4444444444444414
4444444444444415
4444444444444416
4444444444444417
4444444444444418
4444444444444419
4444444444444420
4444444444444421
4444444444444422
4444444444444423
4444444444444424
4444444444444425
4444444444444426
4444444444444427
4444444444444428
4444444444444429
4444444444444430
4444444444444431
4444444444444432
4444444444444433
4444444444444434
4444444444444435
4444444444444436
4444444444444437
4444444444444438
4444444444444439
4444444444444440
4444444444444441
4444444444444442
4444444444444443
4444444444444444
4444444444444445
4444444444444446
4444444444444447
4444444444444448
4444444444444449
44444444444444410
44444444444444411
44444444444444412
44444444444444413
44444444444444414
44444444444444415
44444444444444416
44444444444444417
44444444444444418
44444444444444419
44444444444444420
44444444444444421
44444444444444422
44444444444444423
44444444444444424
44444444444444425
44444444444444426
44444444444444427
44444444444444428
44444444444444429
44444444444444430
44444444444444431
44444444444444432
44444444444444433
44444444444444434
44444444444444435
44444444444444436
44444444444444437
44444444444444438
44444444444444439
44444444444444440
44444444444444441
44444444444444442
44444444444444443
44444444444444444
44444444444444445
44444444444444446
44444444444444447
44444444444444448
44444444444444449
444444444444444410
444444444444444411
444444444444444412
444444444444444413
444444444444444414
444444444444444415
444444444444444416
444444444444444417
444444444444444418
444444444444444419
444444444444444420
444444444444444421
444444444444444422
444444444444444423
444444444444444424
444444444444444425
444444444444444426
444444444444444427
444444444444444428
444444444444444429
444444444444444430
444444444444444431
444444444444444432
444444444444444433
444444444444444434
444444444444444435
444444444444444436
444444444444444437
444444444444444438
444444444444444439
444444444444444440
444444444444444441
444444444444444442
444444444444444443
444444444444444444
444444444444444445
444444444444444446
444444444444444447
444444444444444448
444444444444444449
4444444444444444410
4444444444444444411
4444444444444444412
4444444444444444413
4444444444444444414
4444444444444444415
4444444444444444416
4444444444444444417
4444444444444444418
4444444444444444419
4444444444444444420
4444444444444444421
4444444444444444422
4444444444444444423
4444444444444444424
4444444444444444425
4444444444444444426
4444444444444444427
4444444444444444428
4444444444444444429
4444444444444444430
4444444444444444431
4444444444444444432
4444444444444444433
4444444444444444434
4444444444444444435
4444444444444444436
4444444444444444437
4444444444444444438
4444444444444444439
4444444444444444440
4444444444444444441
4444444444444444442
4444444444444444443
4444444444444444444
4444444444444444445
4444444444444444446
4444444444444444447
4444444444444444448
4444444444444444449
44444444444444444410
44444444444444444411<br

(b) detecting the level of antibody-cadherin complex, and therefrom detecting the presence of cadherin expressing cells in a sample.

79. A method according to claim 78, wherein said antibody is linked to a support material.

80. A method according to claim 79, wherein said antibody is linked to a detectable marker.

81. A method according to claim 80, wherein said detectable marker is a fluorescent marker, and wherein the step of detecting is performed using fluorescence activated cell sorting.

82. A kit for detecting the presence of cadherin-expressing cells in a sample, comprising:

- (a) an antibody that binds to a cyclic peptide according to any one of claims 1-19; and
(b) a detection reagent.

RDX
A3